Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 19;9(3):e91545.
doi: 10.1371/journal.pone.0091545. eCollection 2014.

An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting

Nawaz Hack  1 , Sarah M Fayad  2 , Erin H Monari  1 , Umer Akbar  1 , Angela Hardwick  1 , Ramon L Rodriguez  1 , Irene A Malaty  1 , Janet Romrell  1 , Aparna A Wagle Shukla  1 , Nikolaus McFarland  1 , Herbert E Ward  2 , Michael S Okun  1
Affiliations

An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting

Nawaz Hack et al. PLoS One. .

Abstract

Background: To examine our eight year clinic-based experience in a Parkinson's disease expert clinical care center using clozapine as a treatment for refractory psychosis in Parkinson's disease (PD).

Methods: The study was a retrospective chart review which covered eight years of clozapine registry use. Statistical T-tests, chi-square, correlations and regression analysis were used to analyze treatment response for potential associations of age, disease duration, and Hoehn & Yahr (H&Y) score, and degree of response to clozapine therapy.

Results: There were 36 participants included in the analysis (32 PD, 4 parkinsonism-plus). The characteristics included 30.6% female, age 45-87 years (mean 68.3±10.15), disease duration of 17-240 months (mean 108.14±51.13) and H&Y score of 2 to 4 (mean 2.51±0.51). The overall retention rate on clozapine was 41% and the most common reasons for discontinuation were frequent blood testing (28%), nursing home (NH) placement (11%) and leucopenia (8%). Responses to clozapine across the cohort were: complete (33%), partial (33%), absent (16%), and unknown (16%). Age (r = -0.36, p<0.01) and H&Y score (r = -0.41, p<0.01) were shown to be related to response to clozapine therapy, but disease duration was not an associated factor (r = 0.21, p>0.05).

Conclusions: This single-center experience highlights the challenges associated with clozapine therapy in PD psychosis. Frequent blood testing remains a significant barrier for clozapine, even in patients with therapeutic benefit. Surprisingly, all patients admitted to a NH discontinued clozapine due to logistical issues of administration and monitoring within that setting. Consideration of the barriers to clozapine therapy will be important to its use and to its continued success in an outpatient setting.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Relationship between response to clozapine use and age groups.
Figure 2
Figure 2. Relationship between responses to clozapine when correlated to H&Y scores.
See this image and copyright information in PMC

References

    1. Driver JA, Logroscino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72 5: 432–438. - PMC - PubMed
    1. Pollak P, Tison F, Rascol O, Destee A, Pere J, et al. (2004) Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75 5: 689–695. - PMC - PubMed
    1. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, et al. (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27 4: 153–156. - PubMed
    1. Merims D, Balas M, Peretz C, Shabtai H, Giladi N (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 29 6: 331–337. - PubMed
    1. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59 Suppl 3: 3–7. - PubMed

MeSH terms